Comparative Pharmacology
Head-to-head clinical analysis: TRELSTAR versus VANTAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRELSTAR versus VANTAS.
TRELSTAR vs VANTAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) agonist. Chronic administration suppresses pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, leading to reduced testicular and ovarian steroidogenesis.
Gonadotropin-releasing hormone (GnRH) agonist; continuous stimulation suppresses pituitary gonadotropin secretion, resulting in decreased testosterone production.
3.75 mg intramuscularly once every 4 weeks or 11.25 mg intramuscularly once every 12 weeks or 22.5 mg intramuscularly once every 24 weeks.
10 mg subcutaneously every 24 weeks.
None Documented
None Documented
Terminal elimination half-life approximately 3 weeks (21-28 days) after intramuscular injection; sustained release formulation results in prolonged exposure.
Terminal elimination half-life approximately 4 weeks (28 days) due to continuous release from the implant; after implant removal, plasma concentrations decline with a half-life of about 3-4 days.
Primarily hepatic metabolism; <5% excreted unchanged in urine; fecal elimination of metabolites accounts for approximately 20-30%.
Renal: negligible. Fecal: ~100% (unchanged drug). Histrelin is not metabolized and is excreted unchanged in feces via biliary elimination.
Category C
Category C
GnRH Agonist
GnRH Agonist